Literature DB >> 23765345

IL-12-mediated STAT4 signaling and TCR signal strength cooperate in the induction of CD40L in human and mouse CD8+ T cells.

Regina Stark1, Anett Hartung, Dietmar Zehn, Marco Frentsch, Andreas Thiel.   

Abstract

CD40L is one of the key molecules bridging the activation of specific T cells and the maturation of professional and nonprofessional antigen-presenting cells including B cells. CD4(+) T cells have been regarded as the major T-cell subset that expresses CD40L upon cognate activation; however, we demonstrate here that a putative CD8(+) helper T-cell subset expressing CD40L is induced in human and murine CD8(+) T cells in vitro and in mice immunized with antigen-pulsed dendritic cells. IL-12 and STAT4-mediated signaling was the major instructive cytokine signal boosting the ability of CD8(+) T cells to express CD40L both in vitro and in vivo. Additionally, TCR signaling strength modulated CD40L expression in CD8(+) T cells after primary differentiation in vitro as well as in vivo. The induction of CD40L in CD8(+) T cells regulated by IL-12 and TCR signaling may enable CD8(+) T cells to respond autonomously of CD4(+) T cells. Thus, we propose that under proinflammatory conditions, a self-sustaining positive feedback loop could facilitate the efficient priming of T cells stimulated by high affinity peptide displaying APCs.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23765345     DOI: 10.1002/eji.201243218

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  A novel modulation of structural and functional changes of mouse bone marrow derived dendritic cells (BMDCs) by interleukin-2(IL-2).

Authors:  Xiaofang Hu; Yan Cao; Yiming Meng; Mingxiao Hou
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  The role of CD4(+) T cells in BKV-specific T cell immunity.

Authors:  B J D Weist; M Schmueck; H Fuehrer; A Sattler; P Reinke; N Babel
Journal:  Med Microbiol Immunol       Date:  2014-07-23       Impact factor: 3.402

3.  CD40L confers helper functions to human intra-melanoma class-I-restricted CD4+CD8+ double positive T cells.

Authors:  Tiphaine Parrot; Romain Oger; Houssem Benlalam; Diane Raingeard de la Blétière; Nicolas Jouand; Anne Coutolleau; Laurence Preisser; Amir Khammari; Brigitte Dréno; Philippe Guardiola; Yves Delneste; Nathalie Labarrière; Nadine Gervois
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

4.  Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies.

Authors:  Taweewun Hunsawong; Sineewanlaya Wichit; Thipwipha Phonpakobsin; Yongyuth Poolpanichupatam; Chonticha Klungthong; Napaporn Latthiwongsakorn; Butsaya Thaisomboonsuk; Rawiwan Im-Erbsin; In-Kyu Yoon; Damon W Ellison; Louis R Macareo; Anon Srikiatkhachorn; Robert V Gibbons; Stefan Fernandez
Journal:  Heliyon       Date:  2017-03-21

Review 5.  Using CRISPR to enhance T cell effector function for therapeutic applications.

Authors:  Julian J Freen-van Heeren
Journal:  Cytokine X       Date:  2020-12-21

6.  Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L.

Authors:  Diana Llopiz; Eduardo Huarte; Marta Ruiz; Jaione Bezunartea; Virginia Belsúe; Aintzane Zabaleta; Juan J Lasarte; Jesús Prieto; Francisco Borrás-Cuesta; Pablo Sarobe
Journal:  Oncoimmunology       Date:  2013-12-05       Impact factor: 8.110

7.  Phenotypic and functional characteristics of IL-21-expressing CD8(+) T cells in human nasal polyps.

Authors:  Li Xiao; Lei Jia; Lu Bai; Long He; Binyan Yang; Changyou Wu; Huabin Li
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379

8.  CD40L Expression Allows CD8+ T Cells to Promote Their Own Expansion and Differentiation through Dendritic Cells.

Authors:  Neil Q Tay; Debbie C P Lee; Yen Leong Chua; Nayana Prabhu; Nicholas R J Gascoigne; David M Kemeny
Journal:  Front Immunol       Date:  2017-11-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.